Valuation: NovoCure Limited

Market Cap 1.25B 1.14B 1.05B 956M 1.79B 116B 1.88B 12.79B 5.08B 63.33B 4.7B 4.6B 199B P/E 2026 *
-10.2x
P/E 2027 * -14.7x
Enterprise Value 1.15B 1.04B 962M 875M 1.64B 106B 1.73B 11.71B 4.66B 58B 4.3B 4.21B 182B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.29x
Free-Float
90.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
1 week-9.47%
Current month-18.56%
1 month-31.83%
3 months-39.73%
6 months-39.66%
Current year-17.17%
1 week 10.54
Extreme 10.5412
11.72
1 month 10.54
Extreme 10.5412
15.66
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
120.03
10 years 6
Extreme 6
232.76
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
02/11/26 Sell

Head of Human Resources

-660 0.0006%
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

Head of Human Resources

1,905 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-9.47%-6.54%-12.14% 1.25B
-0.84%-5.09%-16.92%+1.78% 178B
-0.67%-2.84%+0.59%+32.97% 122B
-0.98%+0.12%-14.00%+7.16% 118B
-1.24%-4.25%-43.89%-1.12% 88.1B
-0.63%-5.55%-6.35%+73.06% 64.71B
+0.05%-2.41%+12.24%-8.94% 57.96B
-1.95%-3.98%-1.91%+42.98% 53.28B
-2.91%-4.35%-0.82%+38.03% 47.8B
-1.64%+1.50%+2.30%-1.14% 35.65B
Average -1.06%-3.31%-7.53%+17.26% 77B
Weighted average by Cap. -1.04%-2.98%-10.73%+17.40%

Financials

2026 *2027 *
Net sales 740M 674M 621M 565M 1.06B 68.54B 1.11B 7.56B 3B 37.44B 2.78B 2.72B 117B 809M 737M 679M 618M 1.16B 74.94B 1.22B 8.27B 3.29B 40.93B 3.04B 2.97B 128B
Net income -122M -111M -102M -93.14M -175M -11.3B -184M -1.25B -495M -6.17B -458M -448M -19.37B -79.32M -72.25M -66.57M -60.55M -114M -7.35B -119M -810M -322M -4.01B -298M -291M -12.59B
Net Debt -105M -96.07M -88.52M -80.52M -151M -9.77B -159M -1.08B -428M -5.33B -396M -387M -16.74B -210M -191M -176M -160M -301M -19.44B -316M -2.14B -852M -10.62B -788M -771M -33.32B
Projected Income Statement - Annual - NovoCure Limited
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
20/11/26 US$10.71 +0.19% 1,639,199
19/11/26 US$10.69 -0.37% 1,604,150
18/11/26 US$10.73 -3.68% 1,411,353
17/11/26 US$11.14 -1.42% 1,442,882
16/11/26 US$11.30 -4.48% 2,438,133
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - NovoCure Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.71USD
Average target price
26.14USD
Spread / Average Target
+144.10%
  1. Stock Market
  2. Stocks
  3. NVCR Stock